title: Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.
abstract: The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be better than chemotherapy alone, even in selected wild-type KRAS populations. A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials.
authors.affiliation: Service d'Oncologie Médicale, Hôpital Saint-Antoine, Assistance Publique des Hôpitaux de Paris, Paris, France.
authors.forename: Benoist
authors.initials: B
authors.lastname: Chibaudel
authors.forename: Christophe
authors.initials: C
authors.lastname: Tournigand
authors.forename: Thierry
authors.initials: T
authors.lastname: André
authors.forename: Annette K
authors.initials: AK
authors.lastname: Larsen
authors.forename: Aimery
authors.initials: A
authors.lastname: de Gramont
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D009367:Neoplasm Staging
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents